# The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine

> **NCT05056519** · PHASE1 · UNKNOWN · sponsor: **Changchun BCHT Biotechnology Co.** · enrollment: 160 (estimated)

## Conditions studied

- Influenza Prevention

## Interventions

- **BIOLOGICAL:** Live Attenuated Influenza Vaccine
- **BIOLOGICAL:** Live Attenuated Influenza Vaccine placebo

## Key facts

- **NCT ID:** NCT05056519
- **Lead sponsor:** Changchun BCHT Biotechnology Co.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-20
- **Primary completion:** 2021-12-30
- **Final completion:** 2022-03-30
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2021-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05056519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05056519, "The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05056519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*